Reasons why few patients with acute stroke receive tissue plasminogen activator

Kara Z. Bambauer, S. Claiborne Johnston, Derek E Bambauer, Justin A. Zivin

Research output: Contribution to journalArticle

94 Citations (Scopus)

Abstract

Despite the US Food and Drug Administration's approval in 1996, tissue plasminogen activator (tPA) therapy for acute ischemic stroke remains substantially underused. We reviewed 3 potential reasons for low rates of tPA use: poor patient education, physicians' perceived risk of legal liability from negative patient outcomes, and insufficient reimbursement. The recent addition of diagnosis-related grouping code 559 will provide higher payment for stroke patients treated with tPA, creating a natural experiment to examine our third reason.

Original languageEnglish (US)
Pages (from-to)661-664
Number of pages4
JournalArchives of Neurology
Volume63
Issue number5
StatePublished - May 2006
Externally publishedYes

Fingerprint

Tissue Plasminogen Activator
Stroke
Drug Approval
Legal Liability
Patient Education
Physicians
Food
Therapeutics
Liability
Grouping
Food and Drug Administration
Therapy
Experiment

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Reasons why few patients with acute stroke receive tissue plasminogen activator. / Bambauer, Kara Z.; Johnston, S. Claiborne; Bambauer, Derek E; Zivin, Justin A.

In: Archives of Neurology, Vol. 63, No. 5, 05.2006, p. 661-664.

Research output: Contribution to journalArticle

Bambauer, KZ, Johnston, SC, Bambauer, DE & Zivin, JA 2006, 'Reasons why few patients with acute stroke receive tissue plasminogen activator', Archives of Neurology, vol. 63, no. 5, pp. 661-664.
Bambauer, Kara Z. ; Johnston, S. Claiborne ; Bambauer, Derek E ; Zivin, Justin A. / Reasons why few patients with acute stroke receive tissue plasminogen activator. In: Archives of Neurology. 2006 ; Vol. 63, No. 5. pp. 661-664.
@article{530555e5e3814e2e8004e3ac1d9196f3,
title = "Reasons why few patients with acute stroke receive tissue plasminogen activator",
abstract = "Despite the US Food and Drug Administration's approval in 1996, tissue plasminogen activator (tPA) therapy for acute ischemic stroke remains substantially underused. We reviewed 3 potential reasons for low rates of tPA use: poor patient education, physicians' perceived risk of legal liability from negative patient outcomes, and insufficient reimbursement. The recent addition of diagnosis-related grouping code 559 will provide higher payment for stroke patients treated with tPA, creating a natural experiment to examine our third reason.",
author = "Bambauer, {Kara Z.} and Johnston, {S. Claiborne} and Bambauer, {Derek E} and Zivin, {Justin A.}",
year = "2006",
month = "5",
language = "English (US)",
volume = "63",
pages = "661--664",
journal = "Archives of Neurology",
issn = "0003-9942",
publisher = "American Medical Association",
number = "5",

}

TY - JOUR

T1 - Reasons why few patients with acute stroke receive tissue plasminogen activator

AU - Bambauer, Kara Z.

AU - Johnston, S. Claiborne

AU - Bambauer, Derek E

AU - Zivin, Justin A.

PY - 2006/5

Y1 - 2006/5

N2 - Despite the US Food and Drug Administration's approval in 1996, tissue plasminogen activator (tPA) therapy for acute ischemic stroke remains substantially underused. We reviewed 3 potential reasons for low rates of tPA use: poor patient education, physicians' perceived risk of legal liability from negative patient outcomes, and insufficient reimbursement. The recent addition of diagnosis-related grouping code 559 will provide higher payment for stroke patients treated with tPA, creating a natural experiment to examine our third reason.

AB - Despite the US Food and Drug Administration's approval in 1996, tissue plasminogen activator (tPA) therapy for acute ischemic stroke remains substantially underused. We reviewed 3 potential reasons for low rates of tPA use: poor patient education, physicians' perceived risk of legal liability from negative patient outcomes, and insufficient reimbursement. The recent addition of diagnosis-related grouping code 559 will provide higher payment for stroke patients treated with tPA, creating a natural experiment to examine our third reason.

UR - http://www.scopus.com/inward/record.url?scp=33646411233&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646411233&partnerID=8YFLogxK

M3 - Article

C2 - 16682535

AN - SCOPUS:33646411233

VL - 63

SP - 661

EP - 664

JO - Archives of Neurology

JF - Archives of Neurology

SN - 0003-9942

IS - 5

ER -